Burning Rock OncoCompass Target CDx kit enters NMPA priority approval review

PUBT · 1d ago
Burning Rock OncoCompass Target CDx kit enters NMPA priority approval review
  • Burning Rock’s OncoCompass Target CDx Kit entered China’s NMPA priority approval procedure for medical devices on Oct. 10, 2026.
  • The product is an NGS-based liquid biopsy kit for comprehensive genomic profiling using plasma ctDNA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on October 10, 2026, and is solely responsible for the information contained therein.